Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER+, PR+ or HER2+ breast cancer-Reference-Cited by-同舟云学术

Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER+, PR+ or HER2+ breast cancer

Published:2022 Issue:3 Volume:10 Page:418-429
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Wang Xiaozhen¹,He Jiecheng¹²³,Jiang Siyuan¹²³,Gao Yifei¹,Zhang Ling-Kun¹,Yin Liang¹,You Rong¹,Guan Yan-Qing¹²³^ORCID

Affiliation:

1. School of Life Science, South China Normal University, Guangzhou, 510631, China

2. Guangzhou Key Laboratory of Spectral Analysis and Functional Probes, College of Biophotonics, South China Normal University, Guangzhou 510631, China

3. South China Normal University-Panyu Central Hospital Joint Laboratory of Translational Medical Research, Panyu Central Hospital, Guangzhou, 511400, China

Abstract

Tumor heterogeneity is a large challenge to overcome in breast cancer therapy. In this study, we develop one multi-targeted drug delivery system, which could target to BT-474, MCF-7, EMT-6, and MDA-MB-231 cells, and inhibit their growth.

Funder

National Natural Science Foundation of China

Guangdong Province Higher Vocational Colleges and Schools Pearl River Scholar Funded Scheme

Science and Technology Planning Project of Guangdong Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2022/TB/D1TB02056K

Reference53 articles.

1. Breast cancer